Skip to main content

Why the UK's new guidelines on alcohol consumption are misguided

   Dismissing decades of research on alcohol and health, the UK’s new stringent guidelines on drinking bring to mind a quote from champagne lover Sir Winston Churchill: “Statistics are like a lamppost to a drunk; used more for support than illumination.” In announcing the new policy, England’s chief medical officer and neo-prohibitionist Sally Davies scorned the idea that a daily glass of wine could be healthy, proclaiming it an “old wives’ tale” and suggesting a cup of tea instead. The policy is said to be based on the latest statistics, but do these truly shed any new light? We are hardly in the dark about the effects of wine on health, with many thousands of research papers on record.
   Davies’ fundamental mistake is to judge all types of drinking the same while focusing the outcome narrowly on cancer, failing to consider the opposite: that an equally narrow focus on wine drinkers might have different outcomes when overall health is concerned. Nothing in the “latest data” counters the fact that on average, people who drink wine with meals on a daily basis outlive nondrinkers, are healthier, and enjoy a higher quality of life by objective measures. Davies’ advice to avoid any drinking at all several days a week is similarly imprudent as it can only serve to encourage bingeing instead of healthy drinking. All types of drink are not the same, and all types of drinking are also varied in their effect on health.
   The policy shines a spotlight on alcohol and cancer where broad daylight is needed in order to see the whole picture. But even here the statements in the new policy take liberties with the facts, with assertions such as “no level of alcohol consumption is safe” while acknowledging in the same document that drinking within the guidelines carries the same cancer risk as not drinking. But even that self-contradictory statement oversimplifies the question, because the relationship is nonlinear; for wine, many disease conditions including most types of cancer plot out on a J-shaped curve. In other words the risk is lower for moderate drinkers, then about the same, and increasing rapidly with heavy drinking.  Unfortunately for the Brits and their pub culture, the J curve is shallower for beer. Unfortunately for the new policy, it similary fails when alternating drinking and teetotaling.

   Perhaps the UK would do well to heed Churchill’s view on drinking: “I have taken more out of alcohol than alcohol has taken out of me.”

Comments

Popular posts from this blog

Revisiting resveratrol: new findings rekindle anti-aging debate

Just when we thought the bloom was off the rosé for resveratrol, the anti-oxidant polyphenol from red wine with multiple anti-aging properties, along comes new research giving life to the debate. But first a bit of background: As I detailed in my book Age Gets Better with Wine , it is well-documented that wine drinkers live longer and have lower rates of many diseases of aging. Much or the credit for this has been given to resveratrol, though there isn’t nearly enough of it in wine to explain the effects. Nevertheless, I dubbed it the “miracle molecule” and when it was reported to activate a unique life-extension phenomenon via a genetic trigger called SIRT, an industry was born, led by Sirtris Pharmaceuticals, quickly acquired by pharma giant Glaxo. The hope was that resveratrol science could lead to compounds enabling people to live up to 150 years and with a good quality of life. But alas, researchers from other labs could not duplicate the results, and clinical studies disa...

new resveratrol revelations

What a year it has been for resveratrol, the polyphenol molecule from red wine. Last year at this time it was the toast of the town, having been credited with triggering a metabolic change leading to increased lifespan in experimental models, then catapulted into the limelight as a potential cancer cure with clinical trials under the auspices of pharma giant GlaxoSmithKline. Sales of resveratrol supplements were skyrocketing, with audacious claims about weight loss, brain power, and longevity, never mind that none of this had been proven in humans. But with the new year came new controversy. Two of Glaxo’s competitors, Pfizer and Amgen, published their own studies on resveratrol, concluding that the longevity effect was false, an artifact of the testing method. What few clinical trials there are in humans revealed that it is poorly absorbed and doesn’t last very long in the body anyway. Then in November Glaxo abruptly announced the suspension of the clinical trial and all further devel...